StockNews.com Upgrades Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) to Hold

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Sunday.

ATNM has been the subject of several other research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group lifted their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, April 29th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $25.72.

Actinium Pharmaceuticals Stock Down 1.3 %

NYSEAMERICAN ATNM opened at $8.84 on Friday. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The company has a market capitalization of $263.26 million, a PE ratio of -5.17 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. Equities research analysts anticipate that Actinium Pharmaceuticals will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ATNM. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $78,000. Creative Financial Designs Inc. ADV increased its position in Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at approximately $1,033,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.